C
Vertex, Inc. VERX
$36.08 $1.073.06%
Recommendation
Hold
Prev Close
$35.55
Volume
1,204,882
Avg Vol (90D)
1,181,177
Market Cap
$5.62B
Dividend & Yield
--
52-Week Range
$27.22 - $60.71
P/E (TTM)
--
EPS (TTM)
-$0.3407
My Lists My Alerts
Rating
Reward
B
Good
Risk
D
Weak
Rating Factors
Growth Index
Good
Efficiency Index
Fair
Solvency Index
Excellent
Total Return Index
Good
Volatility Index
Fair
Dividend Index
--
Headlines
This New York-Based Private Equity Firm Has $750 Million Invested in Just 2 Stocks
4/1/2025 - 24/7 Wall St.
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
4/1/2025 - Benzinga
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?
4/1/2025 - Yahoo! Finance: News
10 Stocks of the S&P 500 ETF Up More Than 20% in Q1
4/1/2025 - Zacks Investment Research
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
4/1/2025 - Zacks Investment Research
Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?
4/1/2025 - Insider Monkey
Biotech stocks under pressure following FDA's Peter Marks resignation
4/1/2025 - Yahoo! Finance-YouTube
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $567.00 at Bank of America
4/1/2025 - MarketBeat
Vertex Pharmaceuticals price target raised by $12 at RBC Capital, here's why
4/1/2025 - The Fly
dc court backs hhs denying vertexs proposed fertility support coverage program casgevy
4/1/2025 - FiercePharma
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Increased by B. Metzler seel. Sohn & Co. AG
4/1/2025 - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Reduced by Alliancebernstein L.P.
4/1/2025 - MarketBeat
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
3/31/2025 - Benzinga
8 Best Gene-Editing Stocks to Buy
3/31/2025 - Insider Monkey
Vertex non-opioid painkiller Journavx gets mixed ICER review
3/31/2025 - Seeking Alpha - Healthcare
Vertex non-opioid painkiller Journavx gets mixed ICER review
3/31/2025 - SeekingAlpha.com: All News
Intellia Focuses on Pipeline Development Amid Stiff Competition
3/31/2025 - Zacks Investment Research
Jim Cramer on Vertex Pharmaceuticals (VRTX): Revolutionary Pain Drug on the Horizon!
3/31/2025 - Yahoo! Finance: News
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
3/31/2025 - Zacks Investment Research
Vertex Pharmaceuticals price target raised to $567 from $555 at BofA
3/31/2025 - TipRanks Financial Blog
Vertex Pharmaceuticals price target raised by $12 at BofA, here's why
3/31/2025 - The Fly
Clearbridge Investments LLC Has $745.34 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
3/31/2025 - MarketBeat
California Public Employees Retirement System Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
3/31/2025 - MarketBeat
Allstate Corp Makes New $3.07 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
3/31/2025 - MarketBeat
vertex abandons islet cell device combo after it failed improve diabetes biomarker
3/31/2025 - FierceBiotech.com - Biotech
Income Statement
Total Revenue (TTM)
$666.78M
EBITDA (TTM)
$26.02M
EBIT (TTM)
$18.84M
Net Income (TTM)
-$52.73M
Balance Sheet
Total Assets (Q)
$1.17B
Total Debt (Q)
$351.89M
Total Liabilities (Q)
$987.44M
Book Value Per Share (Q)
$1.14
Cash Flow
Cash from Operations (TTM)
$164.82M
Cash from Investing (TTM)
-$158.15M
Cash from Financing (TTM)
$231.26M
Net Change in Cash (TTM)
$236.92M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.32
7-Day Total Return
-0.22%
30-Day Total Return
-22.43%
60-Day Total Return
-32.37%
90-Day Total Return
-26.52%
Year to Date Total Return
-32.18%
1-Year Total Return
12.64%
2-Year Total Return
83.24%
3-Year Total Return
140.85%
5-Year Total Return
--
52-week Low
Apr 23, 2024 - $27.22
52-week High
Feb 06, 2025 - $60.71
Valuation
Market Cap
$5.62B - Mid Cap
Enterprise Value
$5.67B
Price/Sales (TTM)
8.33
Price/Book (Q)
31.15
Dividends and Shares
Shares Outstanding
156.26M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.vertexinc.com
Phone Number
800 355 3500
Address
2301 Renaissance Boulevard
King of Prussia, PA 19406
Country
United States
Year Founded
1978
Business Description
Sector
Information Technology
Industry
Software and Services
Vertex, Inc., together with its subsidiaries, provides enterprise tax technology solutions for retail trade, wholesale trade, and manufacturing industries in the United States and... more
NASDAQ 04/01/2025 4:00PM Eastern Quotes delayed
Weiss Ratings